| P2093 | author name string | David A Mankoff | |
| | Evan Y Yu | |
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| | Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development | Q28245741 |
| | Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 |
| | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 |
| | ACRIN--lessons learned in conducting multi-center trials of imaging and cancer | Q30438990 |
| | High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors | Q33221053 |
| | Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group | Q33837310 |
| | The role of nuclear medicine in monitoring treatment in skeletal malignancy. | Q34295749 |
| | In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography | Q35596074 |
| | Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy | Q35793157 |
| | Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. | Q35862872 |
| | Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. | Q35874704 |
| | Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer | Q35886293 |
| | PET/CT scanner instrumentation, challenges, and solutions | Q35920189 |
| | Androgen deprivation therapy for prostate cancer | Q36193125 |
| | Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development | Q53656328 |
| | Synthesis and evaluation of a 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET. | Q53659663 |
| | Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. | Q53937139 |
| | Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. | Q54117465 |
| | Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases | Q57693579 |
| | The progress and promise of molecular imaging probes in oncologic drug development | Q36318111 |
| | The future in diagnosis and staging of lung cancer: positron emission tomography | Q36470628 |
| | Cancer biomarkers: a systems approach | Q36561609 |
| | Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma | Q36715057 |
| | The Clinical Applications of Cell Kinetics in Cancer Therapy | Q39624014 |
| | Positron emission tomography imaging--technical considerations | Q39727022 |
| | Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody | Q40177482 |
| | Chiral dimethylamine flutamide derivatives--modeling, synthesis, androgen receptor affinities and carbon-11 labeling | Q40294010 |
| | Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET. | Q40396302 |
| | Prostate cancer PET bioprobes: synthesis of [18F]-radiolabeled hydroxyflutamide derivatives | Q40401095 |
| | In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics | Q40403332 |
| | Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer | Q40547681 |
| | Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors | Q40565368 |
| | Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. | Q40813713 |
| | PET radiopharmaceuticals: state-of-the-art and future prospects | Q40846516 |
| | Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer | Q42545335 |
| | Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression | Q43599677 |
| | Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy | Q44108156 |
| | Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis | Q44112074 |
| | Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma | Q44114749 |
| | Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride | Q44306091 |
| | Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report | Q44374111 |
| | 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. | Q44432100 |
| | Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate | Q44478859 |
| | 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). | Q44574659 |
| | Using Positron Emission Tomography 2-Deoxy-2-[18F]Fluoro-D-Glucose, 11CO, and 15O-Water for Monitoring Androgen Independent Prostate Cancer | Q44589733 |
| | Prediction of survival in glioma patients by means of positron emission tomography | Q44605744 |
| | Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment | Q44780586 |
| | 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial | Q44799714 |
| | Production of [F-18]fluoroannexin for imaging apoptosis with PET. | Q44802190 |
| | 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer | Q44820382 |
| | Positron tomographic assessment of androgen receptors in prostatic carcinoma | Q45279143 |
| | Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody | Q45285584 |
| | Evaluation of 11C-methionine PET as a surrogate endpoint after treatment of grade 2 gliomas | Q45286248 |
| | Use of positron emission tomography scans in ovarian cancer: a diagnostic technique in search of an indication | Q46722595 |
| | Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning | Q46816760 |
| | [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors | Q46825177 |
| | Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. | Q46872269 |
| | Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone | Q47744334 |
| | Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. | Q48451660 |
| | Kinetics of [methyl-11C]thymidine in patients with squamous cell carcinoma of the head and neck. | Q49102679 |
| | Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). | Q52081295 |
| | Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. | Q52123547 |
| | 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 |
| | Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. | Q53483872 |
| | Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. | Q53496753 |
| | Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). | Q53501330 |
| | PET imaging with [18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. | Q53506378 |
| | Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. | Q53530857 |
| P433 | issue | 5 | |
| P921 | main subject | positron emission tomography | Q208376 |
| | biomarker | Q864574 |
| P304 | page(s) | 659-672 | |
| P577 | publication date | 2007-09-01 | |
| P1433 | published in | Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare | Q15756305 |
| P1476 | title | Positron emission tomography imaging as a cancer biomarker | |
| P478 | volume | 7 | |